Sabine Mueller, MD,PhD



Dr. Mueller is a board-certified neurologist, pediatrician and neuro-oncologist with a research program focused on novel therapies for pediatric gliomas and other malignant brain tumors. She is a Professor of Neurology, Neurosurgery and Pediatrics at the University of California, San Francisco (UCSF) and a Professor of Pediatrics at the University of Zurich, Switzerland. She received her PhD in the Department of Biochemistry in Hamburg, Germany generating gene expression libraries for adult glioblastomas for target identification. Prof. Mueller completed her clinical training in Boston as well as at UCSF. Within the Brain Tumor Research Center located in the Helen Diller Cancer Center at UCSF, she conducts preclinical studies in pediatric brain tumor models to support the rationale for the design of early phase clinical trials for children with brain tumors with a specific focus on children with diffuse midline gliomas (DMGs). On the translational site, she is leading the Pacific Pediatric Neuro-Oncology Consortium ( – a now 22 US based-member institution clinical trial consortium with international expansion (Zurich, Switzerland; Australia; Israel and Netherlands) dedicated to developing new therapies for pediatric and AYA brain tumor patients. She also serves as the clinical lead of the DMG Centre at the Children’s Hospital of Zurich, Switzerland. Together with Dr. Nazarian she is also leading the DMG working group of PNOC. Prof. Mueller has extensive experience in bringing new agents into the clinic-chairing or co-chairing over 15 clinical, multi-center trials and leading large multi-centers studies. She has supervised many multi-site tumor boards and is overseeing the Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma National Brain Tumor Board.



Coming Soon

Jason Fangusaro, MD


Jason Fanusaro, MD is Director of Developmental Therapeutics at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta. Dr. Fangusaro is also Professor of Pediatrics at the Emory University School of Medicine and the Carter S. Martin Endowed Chair. As a clinical member of the pediatric neuro-oncology team, he specializes in treating children with central nervous system malignancies, including brain and spinal cord tumors. He is a member of the Children’s Oncology Group Brain Tumor Steering Committee, serves as the Vice Chair of the Pediatric Brain Tumor Consortium, Is Co-Director of the Radiologic Assessment in Pediatric Neuro-Oncology (RAPNO) initiative and partners with the pharmaceutical industry on investigator-initiated trials. He holds professional memberships with American Society of Clinical Oncology, Society for Neuro-Oncology and Children’s Oncology Group.  Dr. Fangusaro’s primary area of research is the development of early phase clinical trials, novel therapeutics and relevant biologic correlates in an effort to improve survival outcomes and minimize toxicities.  He is a member of both the pediatric low-grade glioma (pLGG) and central nervous system germ cell tumor (CNS GCT) international consensus panels, and also serves as the principal investigator and co-investigator on numerous national clinical trials.

Adam Green, MD


Adam Green, MD, is an Associate Professor of Pediatrics at the University of Colorado School of Medicine and an attending pediatric neuro-oncologist at Children’s Hospital Colorado. He completed his undergraduate degree in neurobiology at Dartmouth College and attended medical school at NYU. He served as a resident and chief resident in pediatrics at the University of Colorado and as a pediatric hematology-oncology fellow at Dana-Farber Cancer Institute and Boston Children’s Hospital. There, he trained in translational research in pediatric brain tumors with Drs. Andrew Kung and Stu Orkin, and in childhood cancer disparities with Dr. Carlos Rodriguez Galindo. His lab investigates novel targets and therapeutic strategies in the treatment of pediatric high-grade glioma (HGG), including diffuse midline glioma (DMG). There are several clinical trials that have opened based on work from his lab, including ACNS1821, the current lead COG trial for newly diagnosed pediatric HGG and DMG patients, which he chairs. He also studies causes and interventions for demographic and socioeconomic outcomes disparities in childhood cancer. Dr. Green has had funding from NIH, St. Baldrick’s Foundation, Alex’s Lemonade Stand Foundation, and Hyundai Hope on Wheels, among others.

Carl Koschmann, MD


Dr. Carl Koschmann is a pediatric neuro-oncologist and the Clinical Scientific Director of the University of Michigan Chad Carr Pediatric Brain Tumor Center, and cares for children and young adults with brain tumors. He specializes in the research and treatment of high-risk brain tumors, including high-grade glioma, diffuse midline glioma (DMG), and diffuse intrinsic pontine glioma (DIPG). His NIH-funded laboratory explores mechanisms by which mutations in these tumors drive their formation and impact treatment response. 

Dr. Koschmann also serves as the Co-Scientific Chair of the Children’s Brain Tumor Network, which is the largest pediatric brain tumor data and sample repository. He is the PI/Co-PI for multiple early phase studies in pHGG/DMG for which his lab performs analysis of correlate tumor and spinal fluid samples. 

“The DIPG/DMG National Brain Tumor Board is a game changer for families and referring physicians of children with DIPG or DMG.  This will allow families to consolidate their time and effort and have a panel of experts review their child’s case and provide advice in real time.  This will be used primarily for families at major “decision forks” — at diagnosis, or post-radiation or at recurrence. We are very excited to be a part of this program which is truly unique.”

Michelle Monje, MD, PHD


Michelle Monje, MD, PhD, is a pediatric neuro-oncologist, a professor of Neurology and Neurological Sciences and a Howard Hughes Medical Institute Investigator at Stanford University. Her research program focuses on DIPG and other diffuse midline gliomas at the intersection of neuroscience, immunology and brain cancer biology. Dr. Monje has led several of her discoveries from basic molecular work to clinical trials. She has been recognized with numerous honors, including an NIH Director’s Pioneer Award, a MacArthur Fellowship and election to the National Academy of Medicine. 

Nicholas Vitanza, MD


Dr. Nicholas Vitanza is an Associate Professor at the University of Washington School of Medicine and a pediatric neuro-oncologist at Seattle Children’s Hospital. He directs the Vitanza Lab at Seattle Research Institute’s Ben Town Center for Childhood Cancer Research and he serves as Seattle Children’s CNS CAR T cell Lead and DIPG Research Lead. Dr. Vitanza completed his pediatric oncology fellowship under the mentorship of Drs. Bill Carroll and Elizabeth Raetz at NYU before completing a neuro-oncology fellowship under the mentorship of Dr. Michelle Monje at Stanford. In the Monje Lab his post-doctoral work focused on combinatorial targeted therapy for DIPG was published in Science Translational Medicine and Cancer Cell. In 2016, he joined Seattle Children’s where he has written and directed 3 CNS CAR T cell trials that have delivered over 260 intracranial CAR T cell doses to children with recurrent CNS tumors and DIPG – with preliminary findings published in Nature Medicine. Through his collaborative laboratory and clinical research programs, Dr. Vitanza aims to optimize epigenetic and immunotherapeutic targeting of pediatric CNS tumors with a goal to rapidly translate findings to the clinic and improve the lives of affected children.